MICIT
Live / Applied — Third extension granted (statement of use) (as of 14 Jan 2026)
What this means for you
Not registered yet, but its 27 Sept 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98200315
- Mark type
- Stylized text
- Filed
- 27 Sept 2023
- Published for opposition
- 02 Jul 2024
- Attorney of record
- Monica Riva Talley
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer, in particular based on nucleic acids and/or proteins; Medicines individually tailored for the respective patient, in particular based on nucleic acids and proteins, namely, pharmaceutical preparations for treatment of cancer
- Class 009 — Scientific and electric apparatus: Scientific apparatus and instruments, namely, downloadable mobile software applications for personalized cancer patient information; Software algorithms, namely, downloadable software programs for detecting and registering mutations in cancer patients
- Class 010 — Medical apparatus: Medical devices, namely, high-throughput analysis devices for next-generation sequencing for gene expression profiling and for the detection of epigenetic changes
- Class 042 — Scientific and technological services: Research and development in the field of cancer immunotherapy, in particular research and development in the field of human and veterinary medical diagnostics and therapy using molecular biological, genetic engineering, biotechnological and/or bioinformatic methods, in particular using next-generation sequencing; Scientific laboratory services and scientific research for medical purposes in the field of oncology, namely, diagnostics of tumor markers for personalized therapy
- Class 044 — Medical, beauty and agricultural services: Medical, veterinary and pharmaceutical consultancy, in particular with regard to the selection of suitable therapies for all types of cancer; Medical services, namely, conducting analyzes and treatments in the field of personalized cancer immunotherapy; Medical services, namely, providing nucleic acid based therapies and checkpoint inhibitors
Owner
- BioNTech SE, Mainz, DE
- BioNTech SE, Mainz, DE
Prosecution history
- 15 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Jan 2026 — SOU EXTENSION 3 GRANTED
- 14 Jan 2026 — SOU EXTENSION 3 FILED
- 14 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 13 Aug 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Aug 2025 — SOU EXTENSION 2 GRANTED
- 12 Aug 2025 — SOU EXTENSION 2 FILED
- 12 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Dec 2024 — SOU EXTENSION 1 GRANTED
- 09 Dec 2024 — SOU EXTENSION 1 FILED
- 09 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 27 Aug 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 02 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Jul 2024 — PUBLISHED FOR OPPOSITION